Podophyllotoxin derivatives: drug discovery and development
- 1 August 1996
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 1 (8) , 343-351
- https://doi.org/10.1016/1359-6446(96)10028-3
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- CELL CYCLE EFFECTS OF THE ANTI-RHEUMATIC AGENT CPH82Rheumatology, 1994
- Pharmacokinetics of Anticancer Drugs in ChildrenClinical Pharmacokinetics, 1987
- Purified podophyllotoxin (CPH-86) inhibits lymphocyte proliferation but augments macrophage proliferationInternational Journal of Immunopharmacology, 1987
- Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouseEuropean Journal of Cancer and Clinical Oncology, 1986
- Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationshipBiochemistry, 1984
- Podophyllum: Suspected Teratogenicity from Topical ApplicationClinical Toxicology, 1980
- Direct Chemotaxis and Leucocyte‐Induced Chemotaxis of Polymorphonuclear LeucocytesScandinavian Journal of Haematology, 1978
- Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivativesPublished by Elsevier ,1975
- Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumorsPublished by Elsevier ,1973
- 4′-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of actionPublished by Elsevier ,1970